The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
Dr Amy B. Cadwallader joins Ethics Talk to discuss her article, coauthored with Kavitha Nallathambi: “How Should Regulators and Manufacturers Prevent Avoidable Deaths of Children From Contaminated Cough Syrup?”
This month, AMA Journal of Ethics theme editor Jacquelyn Nestor, a fifth-year MD/PhD student at Hofstra-Northwell School of Medicine, interviewed Allen Buchanan, PhD, about how we can safely explore cutting-edge biomedical enhancements.
The use of coded patient data for reimbursement purposes can tempt clinicians to exaggerate the severity of the patient's condition, skewing the accuracy of the data and interfering with clinical decision support and research.